Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377605 | 1.00 | EPHX1 (0.34) | EPHX1THRATHRBCYP2C19NAAA | |
| SCHEMBL5370641 | 0.82 | EPHX1 (0.34) | EPHX1CYP2C19NAAAHTTSMN1; SMN2 | |
| SCHEMBL5370637 | 0.82 | EPHX1 (0.34) | EPHX1CYP2C19NAAAHTTSMN1; SMN2 | |
| SCHEMBL5372644 | 0.81 | EPHX1 (0.36) | EPHX1THRATHRBCYP2C19NAAA | |
| SCHEMBL5372637 | 0.81 | EPHX1 (0.36) | EPHX1THRATHRBCYP2C19NAAA | |
| SCHEMBL5370227 | 0.79 | MEN1 (0.34) | KMT2A | |
| SCHEMBL5370232 | 0.79 | MEN1 (0.34) | KMT2A | |
| SCHEMBL1087451 | 0.73 | EPHX1 (0.41) | EPHX1CYP2C19NAAACYP19A1HTT | |
| SCHEMBL1087894 | 0.73 | EPHX1 (0.41) | EPHX1CYP2C19NAAACYP19A1HTT | |
| SCHEMBL5370700 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276622-B2 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20060173221-A1 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1609777-A1 | METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173221-A1 | Method for producing oxygen-containing compound | GPX4, DUOX2, SCO2 | EPHX1 478/4885THRA 4374/4885THRB 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.